Respiratory Infections and Inflammations with CC DRG Reimbursement

DRG 178 encompasses inpatient admissions for respiratory infections and inflammations that have at least one Complication or Comorbidity, such as pneumonia with an underlying comorbid condition. This grouping matters for inpatient reimbursement because the Complication or Comorbidity status alters the Diagnosis-Related Group assignment and influences Medicare payment under the inpatient prospective payment methodology.

DRG 178 Overview

DRG 178 covers hospital admissions for respiratory infections and inflammations where at least one Complication or Comorbidity is present, including conditions such as pneumonia, acute bronchitis, and other lower respiratory tract infections complicated by comorbid illness. This Diagnosis-Related Group groups patients by clinical similarity and resource intensity to determine Medicare payment for the inpatient stay. The presence of a Complication or Comorbidity increases expected resource use compared with cases without Complication or Comorbidity, which affects relative payment under Medicare inpatient prospective payment systems. Understanding this grouping is important for accurate coding and reimbursement classification.

Acute adjunctive therapy trials studying therapies given during the initial hospital stay to reduce respiratory failure and need for mechanical ventilation. These studies enroll adults admitted with community-acquired or acute exacerbations of chronic respiratory infections/inflammations (eg, severe bacterial pneumonia, acute exacerbation of chronic bronchitis with infection) and compare adjunctive anti-inflammatory or mucolytic approaches added to standard antibiotics and supportive care. Results inform in-hospital clinical pathways and resource use (ICU days, ventilator days), which directly affect DRG costs and payer reimbursement decisions.
Comparative effectiveness studies of antibiotic stewardship and diagnostic strategies to shorten length of stay and prevent readmission. These pragmatic trials or cohort studies evaluate different empiric antibiotic durations, rapid pathogen diagnostics, or biomarker-guided de-escalation in adults hospitalized with respiratory infections and comorbidities (eg, COPD, heart failure) to determine impacts on clinical outcomes, antibiotic exposure, and institutional length of stay. Findings are relevant to hospitals and payers because optimized diagnostic and prescribing strategies can lower costly inpatient days, antimicrobial resistance-related complications, and post-discharge utilization.
Post-discharge outcomes and care-transition trials assessing interventions to reduce 30-day readmissions and long-term morbidity after hospitalization for respiratory infections and inflammations. These trials enroll patients at discharge following an index admission described by this DRG and test bundled discharge interventions (eg, tailored home oxygen assessment, early outpatient follow-up, telemonitoring, pulmonary rehabilitation referrals) with outcomes including readmission rates, functional status, and downstream utilization. Such research matters to providers and payers by identifying scalable post-discharge programs that improve recovery, reduce repeat hospitalizations, and shift costs out of the inpatient setting.

Acute adjunctive therapy trials studying therapies given during the initial hospital stay to reduce respiratory failure and need for mechanical ventilation. These studies enroll adults admitted with community-acquired or acute exacerbations of chronic respiratory infections/inflammations (eg, severe bacterial pneumonia, acute exacerbation of chronic bronchitis with infection) and compare adjunctive anti-inflammatory or mucolytic approaches added to standard antibiotics and supportive care. Results inform in-hospital clinical pathways and resource use (ICU days, ventilator days), which directly affect DRG costs and payer reimbursement decisions.
Comparative effectiveness studies of antibiotic stewardship and diagnostic strategies to shorten length of stay and prevent readmission. These pragmatic trials or cohort studies evaluate different empiric antibiotic durations, rapid pathogen diagnostics, or biomarker-guided de-escalation in adults hospitalized with respiratory infections and comorbidities (eg, COPD, heart failure) to determine impacts on clinical outcomes, antibiotic exposure, and institutional length of stay. Findings are relevant to hospitals and payers because optimized diagnostic and prescribing strategies can lower costly inpatient days, antimicrobial resistance-related complications, and post-discharge utilization.
Post-discharge outcomes and care-transition trials assessing interventions to reduce 30-day readmissions and long-term morbidity after hospitalization for respiratory infections and inflammations. These trials enroll patients at discharge following an index admission described by this DRG and test bundled discharge interventions (eg, tailored home oxygen assessment, early outpatient follow-up, telemonitoring, pulmonary rehabilitation referrals) with outcomes including readmission rates, functional status, and downstream utilization. Such research matters to providers and payers by identifying scalable post-discharge programs that improve recovery, reduce repeat hospitalizations, and shift costs out of the inpatient setting.

OpenPayer

Summary & Overview

Respiratory Infections and Inflammations with CC: Inpatient Reimbursement Overview

DRG 178 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes